Thai PBS Thai PBS
Sinovac’s COVID-19 vaccine gains China nod for emergency use in kids, adolescents

Sinovac’s COVID-19 vaccine gains China nod for emergency use in kids, adolescents

14 Sept 02:35 Key points summarised by AI
  • China has approved Sinovac Biotech's COVID-19 vaccine for emergency use in children and adolescents aged 3-17, broadening its national vaccination campaign.
  • Preliminary Phase I and II clinical trials demonstrated the vaccine's effectiveness in triggering an immune response in younger participants, with most adverse reactions being mild.
  • Sinovac has also completed trials for a third booster dose, showing a significant increase in antibody levels, though further long-term observation is required.
  • Other Chinese pharmaceutical companies, including Sinopharm and CanSino Biologics, are also advancing trials or seeking approval for their vaccines in younger age groups.
Read full article
World 1/2
Skip > Skip >